The Next Step of Their Control Is Here …

Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.

4 simple steps to protect your privacy and money before it’s too late.

Brian Beeler Biography and Net Worth

EVP of Horizon Therapeutics Public

Brian Beeler joined Horizon in January 2013 and has more than 15 years of experience providing legal counsel to businesses in the health care and life sciences industries. Before joining Horizon, he served as associate general counsel for Fenwal Inc., a global life sciences manufacturer of products for transfusion medicine. Before Fenwal, he was senior counsel, business development, commercial and research and development, at TAP Pharmaceutical Products and Takeda Pharmaceuticals North America, and also previously served as chief compliance officer at Schwarz Pharma.

Beeler is licensed to practice law in the states of Illinois and Indiana. He received his Juris Doctor from Indiana University School of Law, his Master of Business Administration from Kellogg School of Management at Northwestern University, and his bachelor's degree from Purdue University.

What is Brian K. Beeler's net worth?: The estimated net worth of Brian K. Beeler is at least $4.33 million as of May 6th, 2020. Mr. Beeler owns 37,206 shares of Horizon Therapeutics Public stock worth more than $4,327,058 as of April 26th. This net worth approximation does not reflect any other investments that Mr. Beeler may own. Learn More about Brian K. Beeler's net worth.
How do I contact Brian K. Beeler?: The corporate mailing address for Mr. Beeler and other Horizon Therapeutics Public executives is 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, Dublin L2, D04 C5Y6. Horizon Therapeutics Public can also be reached via phone at (531) 772-2100 and via email at [email protected]. Learn More on Brian K. Beeler's contact information.
Has Brian K. Beeler been buying or selling shares of Horizon Therapeutics Public?: Brian K. Beeler has not been actively trading shares of Horizon Therapeutics Public during the past quarter. Learn More on Brian K. Beeler's trading history.
Who are Horizon Therapeutics Public's active insiders?: Horizon Therapeutics Public's insider roster includes Brian Beeler (EVP), Daniel Camardo (EVP), Sean Clayton (EVP), Aaron Cox (CFO), Geoffrey Curtis (EVP), William Daniel (Director), Michael Desjardin (EVP), Michael Grey (Director), Paul Hoelscher (CFO), Vikram Karnani (EVP), Jeff Kent (Insider), Irina Konstantinovsky (EVP), Miles Mchugh (SVP), Barry Moze (EVP), Andy Pasternak (EVP), Jeffrey Sherman (EVP), Elizabeth Thompson (EVP), and Timothy Walbert (CEO). Learn More on Horizon Therapeutics Public's active insiders.

Brian K. Beeler Insider Trading History at Horizon Therapeutics Public

Brian K. Beeler Buying and Selling Activity at Horizon Therapeutics Public

Horizon Therapeutics Public Company Overview

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; Q32 Bio Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.

Today's Range

Now: $116.30

$116.30

50 Day Range

MA: $115.72

$112.60

$116.30

2 Week Range

Now: $116.30

$60.03

$116.38

Volume

N/A

Average Volume

2,498,525 shs

Market Capitalization

$26.63 billion

P/E Ratio

62.19

Dividend Yield

N/A

Beta

1.03